CA-IKOTEK
20.11.2023 15:01:29 CET | Business Wire | Press release
Ikotek, the leading IoT original design manufacturer (ODM), announces with immediate effect the appointment of Mathi Gurusamy as its new Chief Operating Officer (COO). In his new role, Mathi will be responsible for overseeing the company's day-to-day operations, driving strategic initiatives, and contributing to Ikotek's continued growth and success.
Mathi Gurusamy brings a wealth of expertise with over 20 years of experience in the IoT sector and electronic device industry to Ikotek. Prior to joining Ikotek, Mathi held CEO and COO positions at Mobilogix and Telit for the last 15 years. Most recently, Mathi served as Telit Cinterion’s president of its IoT solutions division after the company had acquired Mobilogix in June 2022. Renowned for his adeptness in transforming start-ups into thriving enterprises, Mathi boasts a proven track record. His achievements include securing Fortune 500 companies as clients and cultivating strategic alliances with pivotal partners in the wireless industry.
With a demonstrated ability to effectively manage and drive critical business requirements, Mathi will play a pivotal role in propelling Ikotek's sustained growth and success. His robust leadership skills and strategic vision will help scale Ikotek's business objectives in the US and globally, ensuring a seamless alignment of the company’s services and delivery functions, and continue to deliver significant business impact to Ikotek’s OEM customers globally.
“We are delighted to welcome Mathi Gurusamy to Ikotek as our new COO,” commented Joe Peterson, Ikotek CEO. “His proven track record in the IoT industry and his strategic mindset make him an excellent fit for our organization. Mathi joining Ikotek is a strong endorsement and I am confident that Mathi's leadership will play a key role in advancing Ikotek's mission and ensuring our continued growth."
Mathi Gurusamy expressed his enthusiasm for joining Ikotek, stating, "I am thrilled to be part of the Ikotek team and excited about the opportunity to contribute to the company's impressive growth history. Ikotek has a strong reputation for innovation and commercial excellence across the IoT ecosystem. The ambitious growth vision and strategy is only possible with the massive investment Ikotek and its parent company Quectel has undertaken. I look forward to working with the most talented team in the industry to drive operational efficiency and deliver excellent value to our customers."
As a vital component of the Quectel family and leveraging the significant eco-system synergies of the parent company, Ikotek stands out as the only global ODM exclusively dedicated to IoT. Providing an all-encompassing suite of IoT solutions, Ikotek serves as a comprehensive one-stop-shop covering design and development, hardware construction, testing and verification, product validation, software development, manufacturing, and certification. This integrated approach ensures the delivery of top-tier products and services aimed at minimizing complexity, accelerating time to market, mitigating risks, and optimizing costs. Ikotek's commitment lies in delivering high-quality solutions that resonate with the evolving demands of the IoT landscape.
About Ikotek USA, Inc.
Headquartered in San Diego, California, Ikotek’s core focus is on the enterprise market as it looks to develop ODM solutions to take full advantage of IoT, covering technologies from cellular connectivity, including NB-IoT and 5G, to satellite connections and from well-established IT to relative newcomers such as artificial intelligence IoT (AIoT).
For more information: www.ikotek.com or LinkedIn
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231120698687/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
